+
Site Tour

5-year outcomes of TMVR for severe symptomatic mitral regurgitation presented at PCR LV 2025 by A. Duncan

Tendyne transcatheter mitral valve replacement (TMVR) demonstrates sustained elimination of severe MR and significant quality of life improvement through 5 years, addressing a critical treatment gap for patients unsuitable for surgical intervention.

Download

LEARN MORE:

Tendyne

Related Resources

bRIGHT clinical data release | PCR LV 2025

The standard of caring for TR

TEER G5 Brochure
2025

Poster: Primary MR in the Very Elderly

Prognosis of TR after MitraClip for MR

TRILUMINATE Pivotal - 2-year update EuroPCR 25

bRIGHT 2-year real-world outcomes

2-year outcomes from the TRILUMINATE Pivotal trial

TRENDING TOPICS

bRIGHT clinical data release | PCR LV 2025

bRIGHT procedural clipping strategy presented at PCR LV 2025 by X. Freixa

Navitor Active-Sealing Cuff

Navitor™ Vision* Valve: PVL sealing by unique design

Navitor Low PPI & Radiopaque Markers

Real-World Experience: 10.6% New PPI With Navitor Vision* Valve After 20 Procedures

CONNEXT


TV
RELATED RESOURCES

EXPAND G4 clinical data release | PCR LV 2025

TriClip Symposium | PCR LV 2025

bRIGHT interview with X. Freixa | PCR LV 2025

Review the Trends | Tricuspid Focus

CONNEXT


LIVE
RELATED EVENTS

Tendyne expanded clinical study | PCR LV 2025

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline